Share on LinkedInShare on LinkedIn

ARTICLE · 01 APRIL 2026

Who Owns An AI-generated Trade Secret?

Imagine a pharmaceutical company that deploys a network of AI agents to accelerate early-stage drug discovery.

United StatesIntellectual Property
Sarah Tishler
Sarah Tishler

Imagine a pharmaceutical company that deploys a network of AI agents to accelerate early-stage drug discovery.

The agents work autonomously, analyzing biological datasets, running simulated trials, identifying molecular structures that human researchers had not considered.

After six months, the system surfaces a novel compound with significant therapeutic potential. No human directed it to find that compound.

No human understands, step by step, why the system arrived at it. The company's scientists can observe the output and validate its promise. But the process that generated it, and the intermediate analytical steps the agents took to get there, exist only inside the model.

Now ask a deceptively simple question: who owns that discovery as a matter of trade secret law?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from